Sage Therapeutics’ (SAGE) “Neutral” Rating Reiterated at HC Wainwright
HC Wainwright reissued their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $12.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $14.00. Several other equities analysts have also recently issued reports on […]
HC Wainwright reissued their neutral rating on shares of Sage Therapeutics (NASDAQ:SAGE – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $12.00 price target on the biopharmaceutical company’s stock, down from their prior price target of $14.00. Several other equities analysts have also recently issued reports on […]
